title: Naives, nonresponders, relapsers: who is there left to treat?
abstract: Hepatitis C has a high prevalence in the United States, and the disease burden of HCV will increase over the next 20 to 30 years by many estimates. Trials to evaluate new therapies and optimize the use of triple drug therapies are needed if HCV is to be successfully controlled and its incumbent morbidity and mortality drastically lowered for all groups of patients. With improvements in ability to achieve SVR with agents such as telaprevir and boceprevir, efforts to improve treatment uptake rates and to re-examine the utility of universal or more inclusive screening for chronic hepatitis C are warranted.
authors.affiliation: Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago Medical Center, Chicago, IL 60637, USA.
authors.forename: Archita P
authors.initials: AP
authors.lastname: Desai
authors.forename: Nancy
authors.initials: N
authors.lastname: Reau
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D017281:Cost of Illness; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000821:virology; D019698:Hepatitis C, Chronic / Q000188:drug therapy; D006801:Humans; D015994:Incidence; D015995:Prevalence; D012008:Recurrence
chemical_list: D000998:Antiviral Agents